Zevra Therapeutics Inc. (ZVRA) — Cash Flow-to-Debt Ratio
Zevra Therapeutics Inc. (ZVRA) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of $4.71 Million could theoretically repay 0% of its total liabilities ($136.95 Million) in one year. See free cash flow generation of Zevra Therapeutics Inc. to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Zevra Therapeutics Inc. Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Zevra Therapeutics Inc. across 13 annual periods. Also explore ZVRA net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Zevra Therapeutics Inc. (2012–2024)
Year-by-year debt coverage analysis for Zevra Therapeutics Inc.. For market capitalisation and broader financial context, see Zevra Therapeutics Inc. (ZVRA) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.50x | $-69.67 Million | $138.46 Million | ▼ -65.7% |
| 2023 | -0.30x | $-33.53 Million | $110.46 Million | ▲ +34.8% |
| 2022 | -0.47x | $-18.72 Million | $40.22 Million | ▼ -126.0% |
| 2021 | 1.79x | $10.44 Million | $5.82 Million | ▲ +7276.5% |
| 2020 | -0.02x | $-1.94 Million | $77.62 Million | ▲ +91.1% |
| 2019 | -0.28x | $-23.74 Million | $84.96 Million | ▲ +51.9% |
| 2018 | -0.58x | $-54.20 Million | $93.31 Million | ▼ -93.0% |
| 2017 | -0.30x | $-33.10 Million | $109.97 Million | ▼ -4.7% |
| 2016 | -0.29x | $-29.77 Million | $103.58 Million | ▲ +6.6% |
| 2015 | -0.31x | $-20.27 Million | $65.84 Million | ▲ +20.3% |
| 2014 | -0.39x | $-14.67 Million | $38.02 Million | ▼ -138.2% |
| 2013 | -0.16x | $-4.33 Million | $26.70 Million | ▲ +87.0% |
| 2012 | -1.25x | $-4.43 Million | $3.56 Million | — |